CEL-SCI Corporation (CVM)
-NYSE MKT | Prev Close: | 1.50 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 8.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 9-Dec-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.47 - 3.90 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 115,977 |
|---|
| Market Cap: | 46.48M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CEL-SCI Corporation Announces 1-for-10 Reverse Stock SplitBusiness Wire(Fri, Sep 20)
- CEL-SCI manufacturing, lab operations deemed compliant with GMP requirementstheflyonthewall.com(Mon, Sep 9)
- CEL-SCI Corporation's Manufacturing and Laboratory Operations Deemed Compliant with GMP Requirements Following Audit by European Union Qualified Person for a Second TimeBusiness Wire(Mon, Sep 9)
- CEL SCI CORP Files SEC form 8-K, Other EventsEDGAR Online(Tue, Sep 3)
- CEL-SCI Announces That NYSE MKT Approves PlanBusiness Wire(Tue, Sep 3)
- CEL SCI CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online(Fri, Aug 30)
- CEL SCI CORP FinancialsEDGAR Online Financials(Tue, Aug 20)
- CEL SCI CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, Aug 9)
- CEL-SCI Corporation Reports Third Quarter 2013 Financial ResultsBusiness Wire(Fri, Aug 9)
- Discounted Price Levels Make CEL-SCI Shares a Solid Speculative "Buy" BetMarketwired(Thu, Aug 1)
- CEL SCI CORP Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, Jul 26)
- CEL-SCI and NIAID Publish Data Showing That CEL-SCI’s LEAPS Technology Halted Progression of Lethal Influenza in Three Different Influenza Virus Strains, Including a Drug-Resistant and a 2009 Pandemic Flu StrainBusiness Wire(Thu, Jul 25)
- CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance PlanBusiness Wire(Fri, Jul 19)
- CEL SCI CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; TranEDGAR Online(Fri, Jul 19)
- CEL-SCI Corporation Announces Results of Annual Shareholders’ Meeting and Adjournment of Meeting to July 25, 2013 with Respect to Proposal Concerning Stock Option PlanBusiness Wire(Wed, Jun 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 184.34 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Sep-13)
: | -0.40 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.20 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
CEL-SCI Corporation engages in the research and development of drugs and vaccines. The companys principal product, Multikine, is under Phase III clinical trial for the treatment of head and neck cancer.
View More